Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research on cells’ ’power centers’ sheds light on AIDS treatments

10.10.2002


Companies that create HIV-AIDS drugs now have key information that could assist in making new medications with fewer side effects.



Researchers Henry Weiner, a professor of biochemistry at Purdue University, Steven Zollo of the National Institute of Standards and Technology and Lauren Wood of the National Cancer Institute, noted the similarity between HIV-AIDS treatment side effects and naturally occurring diseases. Certain HIV-AIDS treatment side effects, such as fat loss and insulin resistance, clinically resemble diseases of the mitochondria, the "power centers" in cells, that affect the functioning of other parts of the cell.

The researchers hypothesized that the drugs to combat HIV infection also might inadvertently affect the functioning of the mitochondria.


"Finding that a drug affects a different target than the one it was designed for is not unusual," said Weiner, an expert on protein processing in the mitochondria. The team speculated that current AIDS treatments using drugs that inhibit HIV proteins also could inhibit a key mitochondrial protein.

This speculation fits the observation by doctors that side effects resembling mitochondrial dysfunction originated after new drugs became part of the standard drug "cocktail" used to treat AIDS patients. Highly Active Antiretroviral Therapy, or HAART, has prolonged the lives of many, but also has been associated with side effects such as diabetes, high cholesterol and the development of fatty deposits.

To test the theory that the drugs were inhibiting the mitochondria, the researchers flooded isolated mitochondria with large amounts of the drugs and then measured the levels of processed protein in the mitochondria.

They found that a number of HIV-AIDS drugs can inhibit mitochondrial processing.

Although these findings suggest a possible link between HIV-AIDS drugs and mitochondrial dysfunction, Weiner said he believes that investigating the mitochondria of patients in treatment, or using tissue culture grown in the lab, is the next step.

"That is the only way to determine whether actual patients taking the medication are more than just slightly compromised by the effects of the HIV-AIDS medication on their mitochondria."

In the interim, Weiner said drug companies may find this information useful in efforts to make medications with fewer side effects.

"Drug companies making new AIDS protease inhibitors can take the enzyme we used and screen new potential drugs and select ones that can fight the virus but not damage the mitochondria," he said.

Drug manufacturers may not have made the connection to the mitochondria because the drugs’ effects are minor, Weiner said.

"The protease inhibitors were weak inhibitors of the mitochondria’s enzymatic processing system," he said. "If they were better inhibitors, that would have likely led to more serious complications in patients."

Weiner also sees other possible impacts from the research, such as potential anticancer treatments. He said scientists might find a "good way to kill tumors," by inhibiting specific enzymes within the tumors’ own mitochondria.

The research was published in the September issue of the Journal Mitochondrion. Weiner’s portion of the research was funded in part by the National Institutes of Health.

Contact: Beth Forbes, (765) 494-2722; forbes@purdue.edu

Source: Henry Weiner, (765) 494-1650; hweiner@purdue.edu

Ag Communications: (765) 494-2722; Beth Forbes, bforbes@aes.purdue.edu

Purdue News Service: (765) 494-2096; purduenews@purdue.edu

Beth Forbes | EurekAlert!
Further information:
http://www.purdue.edu/
http://www.agriculture.purdue.edu/AgComm/public/agnews/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>